Alkermes PLC 10-Q quarterly reports

Alkermes plc announced its second-quarter 2026 financial results, highlighting revenue growth from LUMRYZ and increased operating expenses due to the Avadel acquisition.

Alkermes plc reported a net loss for the first quarter of 2026, primarily driven by expenses related to the recent acquisition of Avadel Pharmaceuticals, while total revenues saw a significant increase.

Alkermes plc reported a decrease in net income from continuing operations for the nine months ended September 30, 2025, while announcing a definitive agreement to acquire Avadel Pharmaceuticals plc for up to $20.00 per share.

Alkermes plc reported a decrease in overall revenue and net income for Q2 2025 due to expected royalty expirations, while showcasing robust growth in proprietary product sales and advancing its neuroscience pipeline with positive clinical trial results for Alixorexton.

Alkermes' Q1 2025 net income from continuing operations decreased to $22.5 million, impacted by lower manufacturing and royalty revenues, partially offset by increased product sales and reduced operating expenses.

Alkermes plc reported increased product sales but a decrease in manufacturing and royalty revenues for the third quarter of 2024, following the conclusion of a key arbitration and the expiration of a royalty agreement.

Alkermes' Q2 2024 results show a decrease in manufacturing and royalty revenue offset by an increase in product sales, alongside strategic moves including the sale of the Athlone facility.

Alkermes reported a net income of $36.8 million for the first quarter of 2024, a significant turnaround from a net loss in the same period last year, primarily driven by increased manufacturing and royalty revenues.